Name | Title | Contact Details |
---|
Sechrist Industries Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Sechrist Industries Inc. is based in Anaheim, CA. You can find more information on Sechrist Industries Inc. at www.sechristind.com
Menopause treatment custom to you.
Worldwide Clinical Trials is a global CRO providing full-service drug development services to the pharmaceutical and biotechnology industries from Early Phase and Bioanalytical Sciences through Phase II and III trials to peri-approval studies. Our team offers clients a wealth of expertise in neuroscience, cardiovascular, inflammation, rare disease, and other therapeutic areas. We successfully manage clinical trials with our own staff across nearly 60 countries in North America, Latin America, Europe, Asia Pacific and Middle East. Our full-service capabilities enable us to meet particular trial requirements without compromising on science, safety or service. Bioanalytical • Method Transfer and Validation • Pharmacokinetic Analysis and Reporting Clinical Research Services • Clinical Pharmacology • Bridging Studies • Dyna-Bridging Studies • Drug-Drug Interactions • Pharmacodynamic Modeling Clinical Development • Protocol Development • Feasibility • Project Management • Medical Monitoring • Clinical Monitoring • Site Management • Data Management • Rater Training • Biostatistics and Data Analysis • Medical Writing • Regulatory Affairs • Quality Assurance • Drug and Supply Depots • Drug Safety Peri-Approval • Product Safety and Pharmacovigilance • Late-Stage Research • Registries and Observational Studies • Health Outcomes, Epidemiology and Risk Management
Burke Williams is a Culver City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.